Whether TROP2-negative tumor cells with TACSTD2 promoter methylation might present resistant cell populations under TROP2 inhibitor treatment with the TROP2-based ADC sacituzumab govitecan needs to be further investigated. Here, TACSTD2 is linked to neoplasm.